Hepatitis C virus (HCV) is a major cause of liver diseases including liver cirrhosis and
hepatocellular carcinoma. Approximately 3% of the world population is infected with HCV …

Viral hepatitis is a leading cause of morbidity and mortality worldwide, but has long been
neglected by national and international policymakers. Recent modelling studies suggest that …

Yeast cell lines were genetically engineered to display Hepatitis C virus (HCV) core antigen
linked to gold binding peptide (GBP) as a dual-affinity biobrick chimera. These …

Background Direct-acting antiviral therapy (DAAs) for hepatitis C infection (HCV) have a
much smaller burden of treatment than interferon-based regimes, require less monitoring …

Abstract Background Hepatitis B (HBV) and C (HCV) are important causes of morbidity and
mortality in people living with human immunodeficiency virus (HIV). The burden of these co …

Nearly 60 million people worldwide are infected with Hepatitis C Virus (HCV), a bloodborne
pathogen which leads to liver cirrhosis and increases the risk of hepatocellular carcinoma …

Marginal zone lymphomas (MZLs) account for between 5% and 17% of all non-Hodgkin's
lymphomas. MZLs consist of 3 different subtypes with extranodal being the most commonly …

Tuberculosis (TB) and hepatitis C virus (HCV) infections are both major public health
problems. Despite high rates of coinfection, there is scarce literature addressing the …

Ribavirin, once a staple of hepatitis C treatment, has significant drawbacks, including
treatment-limiting side effects, the requirement for intensive laboratory monitoring, the need …

Abstract In 2016, the World Health Organization (WHO) released the Global Health Sector
Strategy (GHSS) setting goals for global hepatitis elimination. To inform new or revised viral …